Guidance: Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts
FDA issued guidance on container closure systems and device constituent parts for biosimilar and interchangeable biosimilar products, emphasizing the need for compatibility and functionality data in submissions.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 31, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) facilities developing biosimilar or interchangeable biosimilar products. should confirm how it applies to their specific situation before acting. There is a time constraint attached: No specific deadline; guidance is effective immediately but not mandatory.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
New FDA guidance clarifies expectations for container closure systems and device constituent parts in biosimilar and interchangeable biosimilar product submissions, focusing on compatibility, functionality, and patient safety.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) facilities developing biosimilar or interchangeable biosimilar products.
What you must do
Review the guidance and assess current container closure system and device constituent part data for biosimilar products to ensure alignment with FDA expectations.
Deadline
No specific deadline; guidance is effective immediately but not mandatory.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Novo Nordisk’s Bloomington Plant Receives FDA OAI Designation Following Contamination and Compliance Issues - pharmaceuticalcommerce.com
- Uyghur Forced Labor Prevention Act Entity List
- Final Debarment Order: Ricardo Andres Acuna
- Final Debarment Order: Angela Anatilde Baquero
- Guidance: Assessing Adhesion with Transdermal and Topical Delivery Systems for Abbreviated New Drug Applications